Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows (Unaudited)

v3.8.0.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Cash Flows Used in Operating Activities    
Net loss $ (7,208,000) $ (14,613,000)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 2,813,000 3,490,000
Realignment accrual accretion 29,000
Interest accretion 312,000 1,601,000
Provision for bad debt (6,000) 482,000
Mark to market on warrants 401,000
Amortization of debt issuance costs 117,000
Mark to market on derivatives 61,000
Loss on extinguishment of debt 4,278,000
Reversal of severance accrual (2,034,000)
Non-employee share-based payment 216,000
Stock-based compensation 477,000 109,000
Asset impairment 3,363,000
Change in fair value of contingent consideration (5,776,000) (1,174,000)
Other gains and expenses, net (4,000)
Other changes in assets and liabilities:    
(Increase) decrease in accounts receivable (588,000) 4,639,000
Decrease in unbilled receivable 16,000
Decrease in other current assets 162,000 1,272,000
Decrease in other long-term assets 220,000 754,000
Decrease in accounts payable (2,208,000) (761,000)
Decrease in unearned contract revenue (11,000)
Decrease in accrued salaries and bonus (1,805,000) (685,000)
Decrease in accrued liabilities (2,210,000) (4,561,000)
Decrease in long-term liabilities (106,000) (563,000)
Net cash used in operating activities (12,884,000) (6,617,000)
Cash Flows Used in Investing Activities    
Purchase of property and equipment (29,000)
Net cash used in investing activities (29,000)
Cash Flows From Financing Activities    
Issuance of common stock, net of expenses 24,042,000
Cash paid for repurchase of restricted shares (28,000)
Net cash provided by financing activities 24,014,000
Net increase (decrease) in cash and cash equivalents 11,101,000 (6,617,000)
Cash and cash equivalents - beginning 602,000 8,310,000
Cash and cash equivalents - ending 11,703,000 1,693,000
Cash paid for interest